[1] [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA-A Cancer Journal for Clinicians, 2018, 68(6): 394-424.

[2] [2] CHEN W, ZHENG R, ZHANG S, et al. Report of cancer incidence and mortality in China, 2010［J］. Annals of Translational Medicine, 2014, 2(7): 61.

[3] [3] BIDARD F C, CONFORTI R, BOULET T, et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers［J］. Annals of Oncology, 2007, 18(7): 1285-1286.

[4] [4] HE M Y, RANCOULE C, REHAILIA-BLANCHARD A, et al. Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies［J］. Critical Reviews in Oncology Hematology, 2018, 131: 96-101.

[6] [6] KIM M C, CHOI J E, LEE S J, et al. Coexistent loss of the expressions of BRCA1 and p53 predicts poor prognosis in triple-negative breast cancer［J］. Annals of Surgical Oncology, 2016, 23(11): 3524-3530.

[7] [7] ALY A, GANESAN S. BRCA1, PARP and 53BP1: conditional synthetic lethality and synthetic viability［J］. Journal of Molecular Cell Biology, 2011, 3(1): 66-74.

[8] [8] NA B, YU X, WITHERS T, et al. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation［J］. NPJ Breast Cancer, 2019, 5: 14.

[9] [9] WANG J, SHI M, LING R, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial［J］. Radiotherapy and Oncology, 2011, 100(2): 200-204.

[10] [10] S?DERLUND K, SKOOG L, FORNANDER T, et al. The BRCA1/BRCA2/rad51 complex is a prognostic and predictive factor in early breast cancer［J］. Radiotherapy and Oncology, 2007, 84(3): 242-251.

[11] [11] DROZ-ROSARIO R, LU H, LIU J, et al. Roles of BCCIP deficiency in mammary tumorigenesis［J］. Breast Cancer Research, 2017, 19(1): 115.

[12] [12] HUANG Y Y, DAI L, GAINES D, et al. BCCIP suppresses tumor initiation but is required for tumor progression［J］. Cancer Research, 2013, 73(23): 7122-7133.

[13] [13] ONO T, KITAURA H, UGAI H, et al. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase［J］. The Journal of Biological Chemistry, 2000, 275(40): 31145-31154.

[14] [14] LIU J, YUAN Y, HUAN J, et al. Inhibition of breast and brain cancer cell growth by BCCIPα, an evolutionarily conserved nuclear protein that interacts with BRCA2［J］. Oncogene, 2001, 20(3): 336-345.

[15] [15] MENG X, LIU J, SHEN Z. Genomic structure of the human BCCIP gene and its expression in cancer［J］. Gene, 2003, 302(1/2): 139-146.

[16] [16] REWARI A, LU H, PARIKH R, et al. BCCIP as a prognostic marker for radiotherapy of laryngeal cancer［J］. Radiotherapy and Oncology, 2009, 90(2): 183-188.

[17] [17] LIU X, CAO L, NI J, et al. Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues［J］. International Journal of Oncology, 2013, 43(6): 1925-1934.

[18] [18] LIU J, LU H, OHGAKI H, et al. Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas［J］. BMC Cancer, 2009, 9: 268.

[19] [19] LIN Z, HU B, NI W, et al. Expression pattern of BCCIP in hepatocellular carcinoma is correlated with poor prognosis and enhanced cell proliferation［J］. Tumour Biology, 2016, 37: 16305-16315.

[20] [20] LU H, YUE J, MENG X, et al. BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage［J］. Nucleic Acids Research, 2007, 35(21): 7160-7170.

[21] [21] LU H, GUO X, MENG X, et al. The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair［J］. Molecular and Cellular Biology, 2005, 25(5): 1949-1957.

[22] [22] WRAY J, LIU J, NICKOLOFF J A, et al. Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress［J］. Cancer Research, 2008, 68(8): 2699-2707.

[23] [23] HUHN S C, LIU J, YE C, et al. Regulation of spindle integrity and mitotic fidelity by BCCIP［J］. Oncogene, 2017, 36(33): 4750-4766.

[24] [24] LU H, HUANG Y Y, MEHROTRA S, et al. Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes［J］. PLoS Genetics, 2011, 7(9): e1002291.

[25] [25] DALEY J M, SUNG P. 53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks［J］. Molecular and Cellular Biology, 2014, 34(8): 1380-1388.

[26] [26] GUPTA A, HUNT C R, CHAKRABORTY S, et al. Role of 53BP1 in the regulation of DNA double-strand break repair pathway choice［J］. Radiation Research, 2014, 181(1): 1-8.

[27] [27] BOTHMER A, ROBBIANI D F, DI VIRGILIO M, et al. Regulation of DNA end joining, resection, and immunoglobulin class Switch recombination by 53BP1［J］. Molecular Cell, 2011, 42(3): 319-329.

[28] [28] MISENKO S M, PATEL D S, HER J, et al. DNA repair and cell cycle checkpoint defects in a mouse model of ‘BRCAness’ are partially rescued by 53BP1 deletion［J］. Cell Cycle, 2018, 17(7): 881-891.

[29] [29] BUNTING S F, CALLéN E, WONG N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks［J］. Cell, 2010, 141(2): 243-254.

[30] [30] BOUWMAN P, ALY A, ESCANDELL J M, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers［J］. Nature Structural & Molecular Biology, 2010, 17(6): 688-695.